184 filings
Page 4 of 10
6-K
qhe27 c4ek
19 Oct 21
Current report (foreign)
7:30am
6-K
vldmzlsykh21
12 Oct 21
InflaRx Completes Enrollment of Vilobelimab Phase III Study in Severe COVID-19
7:30am
6-K
2kpk5 hawxrydfnnz
15 Sep 21
Current report (foreign)
4:05pm
6-K
z52ralpy
8 Sep 21
InflaRx to Proceed with Pivotal Development for Vilobelimab in Hidradenitis Suppurativa with New Primary Endpoint
7:30am
6-K
tsnwk17dn4xf9y7d1
26 Aug 21
Deed of Amendment to the Articles of Association of
4:06pm
6-K
5y0awnpk7gwtsx
10 Aug 21
Current report (foreign)
7:31am
6-K
89ihwa8m3puuvp
10 Aug 21
InflaRx Announces Positive Data from Second Interim Analysis
7:30am
6-K
rl2je6 b6h
5 Aug 21
Current report (foreign)
8:23am
6-K
liftcv32pzl0o5 pbms
8 Jun 21
Current report (foreign)
7:30am
6-K
havy4
21 May 21
Tony Gibney Joins InflaRx Board of Directors
8:16am
6-K
e3mqxl4 vfb4u
12 May 21
Current report (foreign)
4:30pm
6-K
lztmpvbh ytx6x
11 May 21
InflaRx Announces Positive Topline Results for Vilobelimab from the U.S. Phase II ANCA-Associated Vasculitis IXPLORE Study
4:30pm
6-K
jtld 0ce9726ou2itr
3 May 21
Current report (foreign)
4:15pm
6-K
um6vdv09cp cus1trl
15 Apr 21
InflaRx Completes Enrollment of Vilobelimab Phase IIa Study
7:30am
6-K
42acrlw 0uixv
25 Mar 21
InflaRx Reports Full Year 2020 Financial & Operating Results
7:28am
6-K
f1karj9sp7gxw5kx9
1 Mar 21
Current report (foreign)
12:00am
424B5
x5e 1c2f7rk
26 Feb 21
Prospectus supplement for primary offering
5:10pm
424B5
rspxw6 rl
24 Feb 21
Prospectus supplement for primary offering
5:16pm
6-K
y1hp cpkhjc
24 Feb 21
Current report (foreign)
4:16pm